

Connecticut Public Act 23-171 Legend Drug Disclosure Details

The following product pricing information is being disclosed as required by Connecticut Public Act 23171, Sec. 5. The notice below provides the Wholesale Acquisition Cost (“WAC”) of the Legend Drug, as well as information on the variation efficacy of the legend drug marketed to different racial and ethnic groups.

The prices listed below are WAC prices as published by Medispan. WAC prices are representative of the price paid by wholesalers, but the actual price paid by consumers may differ significantly from the WAC prices listed below. Further, the WAC prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed.

No clinically significant differences in the pharmacokinetics of TRYVIO (aprocitentan) were observed based on age (18–84 years), sex, race/ethnicity, body weight (44–196 kg), between patients and healthy subjects, mild to severe renal impairment (eGFR ≥ 15 mL/min), or mild to moderate hepatic impairment (Child-Pugh class A to B). The effect of kidney failure (eGFR < 15 mL/min), dialysis, or severe hepatic impairment (childpugh class c) on aprocitentan pharmacokinetics is unknown.

Marketed Product Name	Manufacturer	NDC	Package Size	Package WAC Price
TRYVIO (aprocitentan) 12.5 mg	Idorsia Pharmaceuticals	80491-8012-03	30	\$775.00

WAC Prices Last Updated on: January 1, 2025
©2025 Idorsia Pharmaceuticals, Ltd
US-AP-00107 03/25